Monopar Announces MNPR-101-RIT Abstract Accepted As A Oral Presentation At EANM'24
Portfolio Pulse from Benzinga Newsdesk
Monopar Therapeutics Inc. (NASDAQ:MNPR) announced that its abstract on the evaluation of an anti-uPAR antibody as a radiopharmaceutical for imaging and treatment of solid tumors has been accepted as a 'Top-Rated Oral Presentation' at the EANM 2024 Annual Congress.
June 25, 2024 | 12:12 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Monopar Therapeutics' abstract on anti-uPAR antibody for cancer treatment has been accepted as a top-rated oral presentation at EANM 2024, potentially boosting the company's visibility and credibility in the radiopharma space.
The acceptance of Monopar's abstract as a top-rated oral presentation at a prestigious conference like EANM 2024 is a significant achievement. It enhances the company's visibility and credibility in the radiopharma sector, which could attract investor interest and potentially lead to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100